Association between CD79B expression and polatuzumab vedotin efficacy, and therapy-induced changes in CD79B expression in diffuse large B-cell lymphoma
{{output}}
Polatuzumab vedotin (PV), a CD79B-directed antibody-drug conjugate, is approved for treating diffuse large B-cell lymphoma (DLBCL). However, the clinical relevance of CD79B expression and the frequency of loss or decrease after PV-containing therapy remain unc... ...
